FDA Revokes Emergency Use Authorization for COVID-19 Treatment
The agency revoked EUA status for the monoclonal antibody bamlanivimab to be administered alone to treat mild-to-moderate COVID-19.
FDA announced on April 16, 2021 that it has revoked the Emergency Use Authorization (EUA) for the monoclonal antibody bamlanivimab to be administered alone to treat mild-to-moderate COVID-19 in adults and certain pediatric patients. The decision was based on analysis of scientific data that included a look at SARS-CoV-2 variants that appear to be resistant to bamlanivimab alone. This resistance, according to FDA, resulted in an increased risk of treatment failure, and the agency determined the benefits “no longer outweigh the known and potential risks for its authorized use.” FDA had issued EUA for bamlanivimab to be administered alone to treat mild-to-moderate COVID-19 in November 2020 based on the scientific evidence that was available at the time.
“While the risk-benefit assessment for using bamlanivimab alone is no longer favorable due to the increased frequency of resistant variants, other monoclonal antibody therapies authorized for emergency use remain appropriate treatment choices when used in accordance with the authorized labeling and can help keep high risk patients with COVID-19 out of the hospital,” said Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research, in a press release. “We urge the American public to seek out these therapies when needed while we continue to use the best data available to provide patients with safe and effective treatments during this pandemic.”
Source: FDA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
